Unlocking Potential Cures with CRISPR

Provided By:

Health Advances

September 27, 2021

CRISPR-based gene editing technology is differentiated from other modalities, even traditional gene therapies, unlocking potential cures for a range of indications but also presenting unique developmental challenges. Devising a portfolio strategy for CRISPR-based gene editing therapies requires considering the novel therapeutic potential but also the technical, clinical, and commercial complexities. In this white paper, Health Advances proposes a framework for indication selection and portfolio strategy for CRISPR-based gene editing companies based on a range of factors including unmet need, level of competition, and addressable market size.

Post a Comment

You must be logged in to post a Comment.

FEEDBACK